Skip to menu Skip to content Skip to footer

2020

Journal Article

A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction

Hildebrand, Joanne M., Kauppi, Maria, Majewski, Ian J., Liu, Zikou, Cox, Allison J., Miyake, Sanae, Petrie, Emma J., Silk, Michael A., Li, Zhixiu, Tanzer, Maria C., Brumatti, Gabriela, Young, Samuel N., Hall, Cathrine, Garnish, Sarah E., Corbin, Jason, Stutz, Michael D., Di Rago, Ladina, Gangatirkar, Pradnya, Josefsson, Emma C., Rigbye, Kristin, Anderton, Holly, Rickard, James A., Tripaydonis, Anne, Sheridan, Julie, Scerri, Thomas S., Jackson, Victoria E., Czabotar, Peter E., Zhang, Jian-Guo, Varghese, Leila ... Silke, John (2020). A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction. Nature Communications, 11 (1) 3150, 3150. doi: 10.1038/s41467-020-16819-z

A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction

2020

Journal Article

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis

Pender, Michael P., Csurhes, Peter A., Smith, Corey, Douglas, Nanette L., Neller, Michelle A., Matthews, Katherine K., Beagley, Leone, Rehan, Sweera, Crooks, Pauline, Hopkins, Tracey J., Blum, Stefan, Green, Kerryn A., Ioannides, Zara A., Swayne, Andrew, Aftab, Blake T., Hooper, Kaye D., Burrows, Scott R., Thompson, Kate M., Coulthard, Alan and Khanna, Rajiv (2020). Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI insight, 5 (20) e144624. doi: 10.1172/jci.insight.144624

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis

2020

Journal Article

Overview of new developments in myasthenia gravis therapy

Beer, Reuben and Blum, Stefan (2020). Overview of new developments in myasthenia gravis therapy. Advances in Clinical Neuroscience and Rehabilitation, 19 (4), 28-30. doi: 10.47795/mqnw5770

Overview of new developments in myasthenia gravis therapy

2020

Journal Article

Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review

Lewis, Richard A., Cornblath, David R., Hartung, Hans-Peter, Sobue, Gens, Lawo, John-Philip, Mielke, Orell, Durn, Billie L., Bril, Vera, Merkies, Ingemar S. J., Bassett, Paul, Cleasby, Alexa, van Schaik, Ivo N., Sabet, A., George, K., Roberts, L., Carne, R., Blum, S., Henderson, R., Van Damme, P., Demeestere, J., Larue, S., D’Amour, C., Kunc, P., Valis, M., Sussova, J., Kalous, T., Talab, R., Bednar, M., Toomsoo, T. ... PATH study group (2020). Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review. Journal of the Peripheral Nervous System, 25 (3), 230-237. doi: 10.1111/jns.12402

Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review

2020

Journal Article

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS

Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., Della Porta, M. G., Cazzola, M., DeZern, A. E., Roboz, G. J., Steensma, D. P., Van de Loosdrecht, A. A., Schlenk, R. F., Grau, J., Calvo, X., Blum, S., Pereira, A., Valent, P., Costa, D., Giagounidis, A., Xicoy, B., Doehner, H., Platzbecker, U., Pedro, C., Luebbert, M., Oiartzabal,, Diez-Campelo, M., Cedena, M. T., Machherndl-Spandl, S. ... Sanz, G. (2020). Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia, 35 (3), 835-849. doi: 10.1038/s41375-020-0917-7

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS

2020

Journal Article

Relapse patterns in NMOSD: evidence for earlier occurrence of optic neuritis and possible seasonal variation

Khalilidehkordi, Elham, Clarke, Laura, Arnett, Simon, Bukhari, Wajih, Jimenez Sanchez, Sofia, O'Gorman, Cullen, Sun, Jing, Prain, Kerri M., Woodhall, Mark, Silvestrini, Roger, Bundell, Christine S., Abernethy, David, Bhuta, Sandeep, Blum, Stefan, Boggild, Mike, Boundy, Karyn, Brew, Bruce J., Brown, Matthew, Brownlee, Wallace, Butzkueven, Helmut, Carroll, William M., Chen, Celia, Coulthard, Alan, Dale, Russell C., Das, Chandi, Fabis-Pedrini, Marzena J., Fulcher, David, Gillis, David, Hawke, Simon ... Broadley, Simon A. (2020). Relapse patterns in NMOSD: evidence for earlier occurrence of optic neuritis and possible seasonal variation. Frontiers in Neurology, 11 537, 537. doi: 10.3389/fneur.2020.00537

Relapse patterns in NMOSD: evidence for earlier occurrence of optic neuritis and possible seasonal variation

2020

Journal Article

Screening for anti-NMDAR encephalitis in psychiatry

Warren, Nicola, Flavell, Joshua, O'Gorman, Cullen, Swayne, Andrew, Blum, Stefan, Kisely, Steve and Siskind, Dan (2020). Screening for anti-NMDAR encephalitis in psychiatry. Journal of Psychiatric Research, 125, 28-32. doi: 10.1016/j.jpsychires.2020.03.007

Screening for anti-NMDAR encephalitis in psychiatry

2020

Journal Article

Evaluation of the proposed anti-N-Methyl-D-Aspartate receptor encephalitis clinical diagnostic criteria in psychiatric patients

Warren, Nicola, O’Gorman, Cullen, Blum, Stefan, Kisely, Steve, Swayne, Andrew, Flavell, Joshua and Siskind, Dan (2020). Evaluation of the proposed anti-N-Methyl-D-Aspartate receptor encephalitis clinical diagnostic criteria in psychiatric patients. Acta Psychiatrica Scandinavica, 142 (1), 52-57. doi: 10.1111/acps.13197

Evaluation of the proposed anti-N-Methyl-D-Aspartate receptor encephalitis clinical diagnostic criteria in psychiatric patients

2020

Conference Publication

Real world safety of Alemtuzumab in the treatment of Multiple Sclerosis – Australian cohort study

Corbett, Joel, Blum, Stefan, Boggild, Mike, Broadley, Simon and McCombe, Pamela (2020). Real world safety of Alemtuzumab in the treatment of Multiple Sclerosis – Australian cohort study. 2020 AAN Science Highlights, Online, 14 April 2020. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.94.15_supplement.1499

Real world safety of Alemtuzumab in the treatment of Multiple Sclerosis – Australian cohort study

2020

Conference Publication

Generalised Epileptiform Activity in Anti-Glycine Receptor Antibody Autoimmune Limbic Encephalitis

Beer, Reuben, Singh, Gaurav, Blum, Stefan and Sabet, Arman (2020). Generalised Epileptiform Activity in Anti-Glycine Receptor Antibody Autoimmune Limbic Encephalitis. 2020 AAN Science Highlights, Online, 14 April 2020. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.94.15_supplement.2836

Generalised Epileptiform Activity in Anti-Glycine Receptor Antibody Autoimmune Limbic Encephalitis

2020

Conference Publication

Specific Psychiatric Features Identify Anti-NMDAR Encephalitis Before Neurological Deterioration (4888)

Warren, Nicola, O’Gorman, Cullen, Swayne, Andrew, Siskind, Dan and Blum, Stefan (2020). Specific Psychiatric Features Identify Anti-NMDAR Encephalitis Before Neurological Deterioration (4888). 2020 AAN Science Highlights, Online, 14 April 2020. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.94.15_supplement.4888

Specific Psychiatric Features Identify Anti-NMDAR Encephalitis Before Neurological Deterioration (4888)

2020

Conference Publication

Low dose Rituximab in the treatment of myasthenia gravis

Chan, Fiona, Swayne, Andrew, Gillis, David, Wong, Richard, Walsh, Michael, Henderson, Robert, McCombe, Pamela and Blum, Stefan (2020). Low dose Rituximab in the treatment of myasthenia gravis. 18th Biennial Clinical Neurophysiology Workshop of the Australian and New Zealand Association of Neurologists, Gold Coast, QLD, Australia, 29 September–2 October 2019. E Park, Shannon, Ireland: Elsevier. doi: 10.1016/j.clinph.2019.11.034

Low dose Rituximab in the treatment of myasthenia gravis

2020

Journal Article

The clinical profile of NMOSD in Australia and New Zealand

Bukhari, Wajih, Clarke, Laura, O’Gorman, Cullen, Khalilidehkordi, Elham, Arnett, Simon, Prain, Kerri M., Woodhall, Mark, Silvestrini, Roger, Bundell, Christine S., Ramanathan, Sudarshini, Abernethy, David, Bhuta, Sandeep, Blum, Stefan, Boggild, Mike, Boundy, Karyn, Brew, Bruce J., Brownlee, Wallace, Butzkueven, Helmut, Carroll, William M., Chen, Celia, Coulthard, Alan, Dale, Russell C., Das, Chandi, Dear, Keith, Fabis-Pedrini, Marzena J., Fulcher, David, Gillis, David, Hawke, Simon, Heard, Robert ... Broadley, Simon A. (2020). The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology, 267 (5), 1431-1443. doi: 10.1007/s00415-020-09716-4

The clinical profile of NMOSD in Australia and New Zealand

2019

Journal Article

Psychiatric management of anti-NMDAR encephalitis: a cohort analysis

Warren, Nicola, O'Gorman, Cullen, McKeon, Gemma, Swayne, Andrew, Blum, Stefan and Siskind, Dan (2019). Psychiatric management of anti-NMDAR encephalitis: a cohort analysis. Psychological Medicine, 51 (3) PII S0033291719003283, 1-6. doi: 10.1017/s0033291719003283

Psychiatric management of anti-NMDAR encephalitis: a cohort analysis

2019

Journal Article

Serum and CSF anti-NMDAR antibody testing in psychiatry

Warren, Nicola, Swayne, Andrew, Siskind, Dan, O'Gorman, Cullen, Prain, Kerri, Gillis, David and Blum, Stefan (2019). Serum and CSF anti-NMDAR antibody testing in psychiatry. The Journal of neuropsychiatry and clinical neurosciences, 32 (2), appineuropsych19030079-160. doi: 10.1176/appi.neuropsych.19030079

Serum and CSF anti-NMDAR antibody testing in psychiatry

2019

Journal Article

Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination

Tea, Fiona, Lopez, Joseph A., Ramanathan, Sudarshini, Merheb, Vera, Lee, Fiona X. Z., Zou, Alicia, Pilli, Deepti, Patrick, Ellis, van der Walt, Anneke, Monif, Mastura, Tantsis, Esther M., Yiu, Eppie M., Vucic, Steve, Henderson, Andrew P. D., Fok, Anthony, Fraser, Clare L., Lechner-Scott, Jeanette, Reddel, Stephen W., Broadley, Simon, Barnett, Michael H., Brown, David A., Lunemann, Jan D., Dale, Russell C., Brilot, Fabienne, Sinclair, Adriane, Kermode, Allan G., Kornberg, Andrew, Bye, Annie, McGettigan, Benjamin ... Blum, Stefan (Australasian and New Zealand MOG Study Group member) (2019). Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathologica Communications, 7 (1) 145. doi: 10.1186/s40478-019-0786-3

Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination

2019

Journal Article

Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab

Chan, Fiona, Swayne, Andrew, Gillis, David, Walsh, Michael, Henderson, Robert D., McCombe, Pamela A., Wong, Richard C. and Blum, Stefan (2019). Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab. Journal of Neurology, Neurosurgery and Psychiatry, 90 (8), 1-2. doi: 10.1136/jnnp-2018-319410

Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab

2019

Journal Article

084 Treating yourself: a glucocorticoid secreting tumour suppressing myasthenia gravis (vol 89, pg a34, 2018)

Swayne, Andrew, Lane, Michael, Brown, Helen, Prain, Kerri, Wong, Richard, Gillis, David and Blum, Stefan (2019). 084 Treating yourself: a glucocorticoid secreting tumour suppressing myasthenia gravis (vol 89, pg a34, 2018). Journal of Neurology Neurosurgery and Psychiatry, 90 (4), E3-E3. doi: 10.1136/jnnp-2018-ANZAN.83corr1

084 Treating yourself: a glucocorticoid secreting tumour suppressing myasthenia gravis (vol 89, pg a34, 2018)

2019

Conference Publication

Autoimmune diseases presenting as complex mood disorders

Scott, E., Leweke, F. M., Jones, C., Dale, R., Brown, D., Blum, S., Scott, J., Harris, A., Cripps, S. and Hickie, I. B. (2019). Autoimmune diseases presenting as complex mood disorders. RANZCP 2019 Congress, Cairns, QLD, Australia, 12-16 May 2019. London, United Kingdom: Sage Publications. doi: 10.1177/0004867419836919

Autoimmune diseases presenting as complex mood disorders

2019

Journal Article

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study

Mielke, Orell, Bril, Vera, Cornblath, David R., Lawo, John-Philip, van Geloven, Nan, Hartung, Hans-Peter, Lewis, Richard A., Merkies, Ingemar S.J., Sobue, Gen, Durn, Billie, Shebl, Amgad, van Schaik, Ivo N., Sabet, A., George, K., Roberts, L., Carne, R., Blum, S., Henderson, R., Van Damme, P., Demeestere, J., Larue, S., D'Amour, C., Kunc, P., Valis, M., Sussova, J., Kalous, T., Talab, R., Bednar, M., Toomsoo, T. ... Gable, K. (2019). Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 24 (1), 72-79. doi: 10.1111/jns.12303

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study